Skip to Content

Posts tagged with "Patents and IP"

  • Cancer

    Novartis Loses the Glivec Patent Fight in India

    This story is all over the news today, but it’s my impression that most of the stories leave out crucial details. This is not just a big multinational drug company being put in its place by Indian courts, nor is it some crazy ruling with no basis in fact. Here’s the story, as best I… Read More
  • Patents and IP

    Standard of Care? Not So Fast, Not in the United Kingdom

    Did you know that in the UK, patent law says that using a competitor’s compound as a comparison in a clinical trial is an infringement? I sure didn’t. The government has realized that this rule is much stricter than most other countries, and is moving to change it in a bid to keep more clinical… Read More
  • Patents and IP

    Oops. We Didn’t Mean to Publish That.

    Here’s an interesting situation, courtesy of Retraction Watch – trying to pull back a paper because it disclosed something that was supposed to be the subject of your patent. Say the authors of the paper in the Korean Journal of Physiology and Pharmacology: We regret to inform that the published paper included a few parts… Read More
  • Cancer

    JQ1: Giving Up a Fortune?

    The Atlantic is out with a list of “Brave Thinkers”, and one of them is Jay Bradner at Harvard Medical School. He’s on there for JQ1, a small-molecule bromodomain ligand that was reported in 2010. (I note, in passing, that once again nomenclature has come to the opposite of our rescue, since bromodomains have absolutely… Read More
  • Chemical News

    The American Chemical Society’s Lawsuit Problem

    Since we’ve been talking about the ACS around here recently, I wanted to highlight a decision in a long-running court case the society has been involved in, American Chemical Society v. Leadscope. Rich Apodaca has a summary here of the earlier phases of the suit, which is now in its tenth year in the courts. Read More
  • Patents and IP

    The Myriad Gene Patent Case: Trickier Than You Might Think

    All right, there’s been another ruling in the Myriad gene patent case, involving genetic testing for the BRCA mutations in breast cancer. There’s been a lot of coverage of this, but not all of it gets the details right. And there are a lot of details, so here goes. First off, here is the latest… Read More
  • Patents and IP

    What Compound Are You Trying to Patent, Again?

    I sure hope that Sanofi doesn’t really want to own these compounds in this recent patent filing. (Thanks to a reader at another company for sending this along!) But what are the odds of that, given that they went to all the trouble of filing on them? The reason I say that is while the… Read More
  • Business and Markets

    China’s Compulsory Licensing

    The Chinese government recently amended its intellectual property law to allow for compulsory licensing. Similar measures are on the books in many other companies, and it’s allowed under international patent law (WIPO) in cases of emergency or threats to public health. India recently did this to Bayer’s Nexavar. Thailand has used this p… Read More
  • Patents and IP

    Publishing Without Consent

    Here’s a note on an ugly situation: when a post-doc publishes a paper without the permission of the principal investigator. Now, this is a fairly rare situation, but still not as rare as you might imagine – the article itself has several citations, and it quotes a journal editor who’s seen it happen a number… Read More
  • Drug Development

    A Long-Delayed COX2 Issue Gets Settled – For $450 Million?

    Has the last shot been fired, very quietly, in the COX-2 discovery wars? Here’s the background, in which some readers of this site have probably participated at various times. Once it was worked out that the nonsteroidal antiinflammatory drugs (aspirin, ibuprofen et al.) were inhibitors of the enzyme cyclooxygenase, it began to seem likely th… Read More